Transgene Expression, Durability & Immunogenicity

Are you currently facing challenges with waning efficacy, unexpected immunogenicity, or high-dose requirements in your AAV gene therapy or genetic vaccine programs? Creative Biolabs' NHP Platform helps you accelerate long-term drug development and improve clinical predictability through highly translational in vivo models and advanced bioanalysis.

Unlock Long-Term Efficacy and Safety for Your Genetic Medicines with Our NHPs.

NHP models are the only essential, reliable platform predicting AAV immunogenicity and long-term expression for regulatory approval.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Adeno-Associated Virus (AAV) is the leading vector for in vivo gene delivery, promising both durable, single-administration therapies for genetic diseases and highly effective, single-dose preventative vaccines. The core scientific challenge lies in understanding the vector's long-term fate in a relevant host. In large animal models, transgene expression is often biphasic: an initial high-level, yet transient, peak derived from non-integrated (episomal) vector genomes, followed by a substantial decline to a much lower, stable steady state. This stable, low-level persistence is likely driven by the rare, non-replicative integration of the vector genome into the host chromosome. For genetic vaccines, AAV's stability in the host cell allows for prolonged expression of the target antigen, leading to durable immune responses that far outlast those from traditional platforms. The successful translation of these medicines requires precise measurement of this biphasic expression profile and rigorous monitoring of the host's immune response to both the vector capsid and the therapeutic transgene product.

Why Choose Us?

NHPs, such as the Cynomolgus and Rhesus macaques, are uniquely positioned as the gold standard model for AAV research due to their high degree of similarity to humans in key physiological systems. Creative Biolabs leverages these advantages to provide the highest confidence in your preclinical data:

• Genetic & Immunological Homology: NHPs share immune system complexity, size, and metabolism with humans, providing the only reliable platform for predicting human immune responses (e.g., T-cell activation, anti-drug antibodies) against the AAV capsid and transgene product.
• Predictive Expression Kinetics: NHPs accurately model the biphasic transgene expression profile seen in humans, distinguishing between short-term episomal expression and long-term expression driven by integration or highly stable episomes—a critical distinction that simple rodent models often fail to replicate.
• Clinical Translational Relevance: Dose-escalation, biodistribution, and toxicology data collected in NHPs are mandatory for regulatory submissions to agencies, minimizing the risk of clinical hold.
• Comprehensive Immunomonitoring: The NHP system allows for precise monitoring of Neutralizing Antibody (NAb) titers and cellular immune responses, essential for developing dose-sparing strategies and mitigating the risk of vector- or transgene-mediated immunotoxicity.

Fig.1 Evaluation of expression levels, persistence, and distribution of NHP, human, and non-self NHP transgenes post intravenous delivery of AAV vectors.¹

Key Applications

Our NHP models provide actionable data necessary to refine your vector design and clinical strategy across various genetic applications:

• Long-Term Transgene Persistence: Evaluating Biphasic Expression and Genomic Integration: NHPs allow for prolonged (1-2+ year) follow-up studies to characterize the high initial expression followed by the stable long-term baseline, tracking the rare genomic integration events to confirm vector safety and persistence.
• Comprehensive Immunogenicity Profiling: Predicting and Mitigating Immune Reactions: NHPs are used to measure pre-existing anti-AAV NAb titers, characterize the cellular immune response (T-cell activation, cytokine release), and quantify Anti-Drug Antibodies (ADA) against the therapeutic transgene product.
• Off-Target Safety & Biodistribution: Regulatory Compliance for Vector Shedding and Integration Site Analysis: NHPs are critical for determining the biodistribution and shedding kinetics of the AAV vector across tissues and body fluids, ensuring regulatory compliance. Furthermore, our genomic analysis confirms that integration events are not clustered near oncogenes, ensuring a favorable safety profile.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs provides end-to-end support for your AAV program through specialized NHP-centric services. We do not just perform studies; we capture data points critical for your regulatory filing.

Translational Impact

Leveraging Creative Biolabs' NHP platform dramatically reduces the uncertainty inherent in translating genetic medicines from preclinical to clinical stages.

The high-fidelity data from our NHP models provides crucial regulatory support. By accurately mapping the biphasic transgene expression kinetics observed in NHPs, we reduce the risk of underestimating long-term efficacy declines seen in early human trials. Furthermore, NHP biodistribution and integration safety data are often explicitly required for gene therapy Investigational New Drug (IND) submissions, providing the necessary evidence that rare vector integration events are not clustered near oncogenes, thereby reducing the risk of clinical hold or failure. Our NHP studies significantly increase the probability of successful IND clearance and accelerate the timeline for first-in-human studies.

Frequently Asked Questions

Contact Us

Creative Biolabs offers an integrated NHP service platform, from model selection and bespoke study design to advanced bioanalysis and regulatory-compliant data reporting, all focused on proving the long-term safety and durable efficacy of your AAV gene therapies and genetic vaccines. Contact us and leverage our NHP Expertise for your next study.